Status: Not yet recruiting
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
Participants needed: 26
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: John MascarenhasUpdated: Mar 18, 2026Locations: 3
Eligibility criteria
Adults ≥ 18 years of age capable of providing informed consent [+18]
Prior treatment with Janus kinase (JAK) inhibitors [+18]